Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice.
Hyperlipidemia has been demonstrated to be associated with renal disease, yet the mechanism of renal injury is still poorly understood. Inflammation that occurs with the hyperlipidemia has been considered to play an important role in development of glomerular injury. In the present study, we investigated the role of interleukin-6 (IL-6), a key inflammatory molecule, on renal injury in apolipoprotein E-deficient (ApoE(-/-)) mice with severe hypercholesterolemia. The 6-wk-old mice were fed a high-fat diet and administered weekly rat anti-IL-6 receptor monoclonal antibody (MR16-1), control rat IgG, or saline for a total of 4 wk. We examined histopathological changes in the kidney and urinary excretion of protein and albumin. Saline- and IgG-treated mice showed remarkable proteinuria at 10 wk of age, whereas MR16-1-treated mice exhibited significantly lower levels. Renal histopathology of saline- and IgG-treated mice revealed striking lipid deposits and foam cells in the glomerular tuft, juxtaglomerular area, and arteriolar wall along with range of mesangial cell proliferation and matrix expansion. Notably, the severity of lipid deposits and mesangial cell proliferation were significantly reduced in MR16-1-treated mice. Immunohistochemistry demonstrated that mesangial IL-6 expression was dramatically reduced in MR16-1-treated mice compared with IgG-treated mice. Blocking the IL-6 receptor prevented progression of proteinuria and renal lipid deposit, as well as the mesangial cell proliferation associated with severe hyperlipoproteinemia. These results clearly demonstrate that IL-6 plays an essential role in the pathogenesis of hyperlipidemia-induced glomerular injury in ApoE(-/-) mice and suggests the usefulness of anti-IL-6 receptor antibody in treatments for hyperlipidemia-induced organ damage.
Tomiyama-Hanayama
Mari
M
Department of Geriatric Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Rakugi
Hiromi
H
Kohara
Masaharu
M
Mima
Toru
T
Adachi
Yasuo
Y
Ohishi
Mitsuru
M
Katsuya
Tomohiro
T
Hoshida
Yoshihiko
Y
Aozasa
Katsuyuki
K
Ogihara
Toshio
T
Nishimoto
Norihiro
N
D000419:Albuminuria / Q000276:immunology / Q000517:prevention & control; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001057:Apolipoproteins E / Q000172:deficiency* / Q000235:genetics; D001794:Blood Pressure; D049109:Cell Proliferation; D004195:Disease Models, Animal; D005921:Glomerulonephritis / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D006339:Heart Rate; D006937:Hypercholesterolemia / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D015850:Interleukin-6 / Q000378:metabolism*; D007668:Kidney / Q000276:immunology* / Q000473:pathology; D008297:Male; D050527:Mesangial Cells / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D051381:Rats; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E; D015850:Interleukin-6; D019947:Receptors, Interleukin-6